{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:09:38Z","timestamp":1789430978411,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["209708"],"award-info":[{"award-number":["209708"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019720","name":"GlaxoSmithKline Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019720","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.euf.2022.07.004","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T01:12:54Z","timestamp":1660785174000},"page":"178-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression"],"prefix":"10.1016","volume":"9","author":[{"given":"Stavros","family":"Gravas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Palacios-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Concas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr J.","family":"Kamola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus G.","family":"Roehrborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Oelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Kattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio Augusto","family":"Averbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Manyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zrinka","family":"Lulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2022.07.004_b0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/1756287217742837","article-title":"Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base","volume":"10","author":"Gacci","year":"2017","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.euf.2022.07.004_b0010","doi-asserted-by":"crossref","first-page":"e14250","DOI":"10.1111\/ijcp.14250","article-title":"Real-world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain","volume":"75","author":"Mi\u00f1ana","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euf.2022.07.004_b0015","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","article-title":"EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction","volume":"64","author":"Oelke","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.07.004_b0020","unstructured":"Gravas S, Cornu JN, Gacci M, et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), including benign prostatic obstruction (BPO). Arnhem, The Netherlands: European Association of Urology; 2022. https:\/\/uroweb.org\/guidelines\/management-of-non-neurogenic-male-luts."},{"key":"10.1016\/j.euf.2022.07.004_b0025","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bju.12500","volume":"113","author":"Roehrborn","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2022.07.004_b0030","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1464-410X.2011.10124.x","volume":"107","author":"Roehrborn","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2022.07.004_b0035","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/j.1464-410X.2011.10129.x","volume":"107","author":"Montorsi","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2022.07.004_b0040","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0022-5347(05)00708-1","article-title":"Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo","volume":"175","author":"Crawford","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.07.004_b0045","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","article-title":"Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia","volume":"60","author":"Roehrborn","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.euf.2022.07.004_b0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","article-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study","volume":"57","author":"Roehrborn","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.07.004_b0055","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1464-410X.2011.10195.x","article-title":"Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)","volume":"108","author":"Nickel","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2022.07.004_b0060","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0302-2838(03)00367-1","article-title":"Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride","volume":"44","author":"Barkin","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.07.004_b0065","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/bju.14057","article-title":"A prospective randomised placebo-controlled study of the impact of dutasteride\/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)","volume":"121","author":"Roehrborn","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2022.07.004_b0070","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bju.13033","volume":"116","author":"Roehrborn","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2022.07.004_b0075","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/pcan.2008.49","article-title":"Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH","volume":"12","author":"Chung","year":"2009","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2022.07.004_b0080","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2022.07.004_b0085","first-page":"159","article-title":"Three things that every medical writer should know about statistics","volume":"18","author":"Senn","year":"2009","journal-title":"J Eur Med Writing Assoc"},{"key":"10.1016\/j.euf.2022.07.004_b0090","first-page":"907","article-title":"Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer","volume":"926","author":"Royston","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.euf.2022.07.004_b0095","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euf.2022.07.004_b0100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.urology.2005.07.013","article-title":"Development of a nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia","volume":"67","author":"Slawin","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.euf.2022.07.004_b0105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/bju.12802","article-title":"Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH)","volume":"115","author":"Kozminski","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2022.07.004_b0110","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.juro.2011.12.083","article-title":"Quantifying the contribution of symptoms improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial","volume":"187","author":"Roehrborn","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.07.004_b0115","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0022-5347(01)66780-6","article-title":"Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association Symptoms Index and the Benign Prostatic Hyperplasia Impact Index is perceptible to patients","volume":"154","author":"Barry","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.07.004_b0120","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00345-019-02783-x","article-title":"Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH","volume":"38","author":"D\u2019Agate","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2022.07.004_b0125","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s00345-020-03517-0","article-title":"Impact of early vs. delayed initiation of dutasteride\/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS\/BPH patients with moderate-to-severe symptoms at risk of disease progression","volume":"39","author":"D\u2019Agate","year":"2021","journal-title":"World J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456922001651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456922001651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:54:59Z","timestamp":1762498499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456922001651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2405456922001651"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2022.07.004","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2022.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}